KRTX News and Press, Karuna Therapeutics Inc. From 11/18/19

The stock market got off to a slow start on Monday, but it managed to finish the session with modest gains for most major benchmarks. Concerns about whether the U.S. and China will find a near-term solution to their trade disputes held indexes back from bigger moves higher, but the overall mood ...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an u...

KRTX stock is having its biggest one-day gain and has hit a new high after Karuna Therapeutics Inc (NASDAQ:KRTX) announced positive results from a Phase 2 clinical trial evaluating KarXT in schizophrenic patients with acute psychoses. Investors Cheer the News Whenever a pharmaceutical o...

Gainers:  Karuna Therapeutics (NASDAQ: KRTX ) +282% More news on: Karuna Therapeutics, Inc., Hermitage Offshore Services Ltd., Eltek Ltd., Stocks on the move, Read more ...

Karuna Therapeutics (NASDAQ: KRTX ) +80%  on positive KarXT data . More news on: Karuna Therapeutics, Inc., Eros International Plc, Capstone Turbine Corporation, Stocks on the move, Read more ...

Thinly traded micro cap Karuna Therapeutics (NASDAQ: KRTX ) is up  86%  premarket on light volume in reaction to positive results from a Phase 2 clinical trial evaluating KarXT in schizophrenia patients with acute psychoses. More news on: Karuna Therapeutics, Inc., Healthcare...

KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo Improvement in Total PANSS Score at Five Weeks was 11.6 Points Compared to Placebo (p<0.0001) ...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced it will hold a webcast and...

Karuna Therapeutics (NASDAQ: KRTX ): Q3 GAAP EPS of -$0.39 beats by $0.08 . More news on: Karuna Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the ...